Cooperative Agreement NU58DD000028

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $286,510 Cooperative Agreement under the Blood Disorder Program: Prevention, Surveillance, and Research (CFDA 93.080) to the Center for Public Health Innovation, a woman-owned non-profit organization, for the Sickle Cell Data Collection Program - 2023. This 5-year project, beginning on September 30, 2023, aims to work with state health agencies and other partners to plan, develop, implement, coordinate, and evaluate programs and...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $172,176 Project Grant to Albert Einstein College of Medicine to conduct a pilot study titled "Reducing Morbidity in Sickle Cell Disease-PREVENT Acute Chest Syndrome System (PACSYSTEM) Pilot Study." This 5-year grant, awarded on June 1, 2024, aims to improve health outcomes for children and youth with sickle cell disease by using implementation science methods to address barriers and enablers faced by healthcare...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease (SCD). The key objectives of the research are to: 1) delineate the characteristics of sickle RBCs that contribute to neutrophil activation, 2) examine the...

This $265,347 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The grant recipient, Functional Fluidics Inc., a minority-owned for-profit company in Detroit, Michigan, is developing a rapid, integrated point-of-care testing system to assess red blood cell sickling as an indicator of sickle cell disease (SCD) patient condition and treatment efficacy. The goal is to create a...

This National Heart, Lung, and Blood Institute (NHLBI) Project Grant award under the Cardiovascular Diseases Research program (CFDA 93.837) provides $156,340.00 to the Connecticut Children's Medical Center to develop and test a communication-enhancement intervention for healthcare providers (HCPs) to improve health outcomes in pediatric sickle cell disease (SCD). The 5-year grant will fund research activities including literature reviews, qualitative research with adolescent SCD patients and...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $608,126 to the Regents of the University of Minnesota to conduct research on developing and validating single-cell biomarkers for predicting clinical outcomes in sickle cell disease. The key objectives are to: 1) define the relationship between common sickle cell disease adverse outcomes and single-cell biochemical and mechanical...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...

This Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on developing a high-throughput platform to measure the equilibrium and kinetics of hemoglobin polymerization in single red blood cells. The $483,852 award will enable the primary grantee, The General Hospital Corporation (dba Massachusetts General Hospital), to create this novel platform technology to optimize the development...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under CFDA 93.865 - Child Health and Human Development Extramural Research program will support research to assess the safety of different hormonal contraceptive methods for individuals with sickle cell disease (SCD). The $469,500 award to Emory University will leverage health system data to compare risks of SCD complications such as venous thromboembolism and stroke between estrogen-containing and...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $169,156 to The Washington University in St. Louis to support a 5-year research program focused on optimizing hematopoietic stem cell transplantation (HSCT) to treat non-malignant diseases, particularly sickle cell disease (SCD). The key objectives are to: 1) Evaluate novel stem cell mobilization regimens combining VLA-4 and CXCR4 inhibition to generate...